



Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Current Evidence and Future Insights

Guest Editors:

Dr. Soheil Ebrahimpour

Infectious Diseases and Tropical
Medicine Research Center,
Health Research Institute, Babol
University of Medical Sciences,
Babol, Iran

Dr. Mostafa Javanian

Infectious Diseases and Tropical
Medicine Research Center,
Health Research Institute, Babol
University of Medical Sciences,
Babol, Iran

Deadline for manuscript
submissions:

closed (1 April 2024)

Message from the Guest Editors

COVID-19 vaccination, a treatment which minimizes the rates of infection and major complications of the disease, is amongst the most effective plans for controlling the current COVID-19 pandemic. However, in addition to these benefits of vaccinations, at the beginning of 2021, a prothrombotic syndrome was encountered for the first time in some of the recipients of the ChAdOx1 CoV-19 vaccine. Since the hallmark of this syndrome was the development of thrombosis and/or thrombocytopenia between 5–30 days after vaccination (ChAdOx1 nCoV-19 or Ad26.COV2.S), it was named vaccine-induced immune thrombotic thrombocytopenia (VITT). Therefore, some concerns were raised about an increased risk of VITT among individuals who had received COVID-19 vaccines. On these bases, it is clear that there are several essential trending topics remaining to work on in terms of COVID-19 VITT. The Special Issue aims to identify and fill important knowledge gaps including potential mechanisms, clinical implications, diagnosis, and management of COVID-19 VITT.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com